Aragon obtains $42M in funding for cancer drug development

03/7/2012 | Genetic Engineering & Biotechnology News

Aragon Pharmaceuticals secured $42 million in a Series C funding round headed by new investor Topspin Fund. The money will be used to advance the development of Aragon's early clinical and preclinical androgen receptor- and estrogen receptor-targeting drugs for certain prostate and breast cancers.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Paralegal
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA